pfizer glp 1 oral discontinues GLP-1 receptor agonist danuglipron China approves Pfizer GLP-1 drug
Description
Oral semaglutides efficacy in trials (PIONEER program) was similar to weekly injection: A1c reductions ~1.01.4% with 14 mg daily, weight loss ~34 kg ( [135] )
[67] CHIP, Medicaid, and Medicare Coverage [edit] In April 2025, the Trump Administration declined to finalize a Biden Administration proposal that would have required Medicare, Medicaid, and the Children's Health Insurance Program (CHIP) to broadly cover GLP-1 drugs for weight loss
Carlos E
Still, they are not a cure-all
In 2005, the FDA approved Byetta for type 2 (adult-onset) diabetes, which was quickly followed by others such as Ozempic and Wegovy
00360-0/asset/06397771-b461-4bfd-bc69-cd0a43d464aa/main.assets/fx1.jpg)
